This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (48)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Judith M. E. Walsh, MD, MPH; Deborah Grady, MD, MPH

JAMA. 1995;274(14):1152-1158.

Abstract
Objective.
—To assess the evidence that lipid lowering prevents coronary heart disease (CHD) events in women.

Data Sources.
—English-language literature assessing the effects of cholesterol lowering with dietary and/or drug interventions as primary or secondary prevention on CHD events in women.

Main Outcome Measures.
—Coronary heart disease and total mortality were the primary outcomes assessed. Angiographic regression of coronary atherosclerosis was a secondary outcome.

Study Selection, Data Extraction, and Data Synthesis.
—All nine of the identified studies that met the criteria were included. Relative risks for CHD and total mortality were calculated from available data. Summary relative risks were calculated using meta-analytic techniques.

Conclusions.
—There is no evidence from primary prevention trials that cholesterol lowering affects total mortality in healthy women, although the available data are limited. Limited evidence suggests that treatment of hypercholesterolemia in women with coronary disease may decrease CHD mortality. Future research should address the role of dietary and other nondrug treatment of hypercholesterolemia in women at high risk for CHD.

(JAMA. 1995;274:1152-1158)

Author Affiliations
From the Department of Medicine, University of California San Francisco/Mount Zion, (Dr Walsh), the Veterans Affairs Medical Center, General Internal Medicine Section, San Francisco (Dr Grady), and Department of Epidemiology and Biostatistics, University of California, San Francisco (Dr Grady).

Footnotes
Reprint requests to the Department of Medicine, University of California, San Francisco/Mount Zion, Box 1610, San Francisco, CA 94115 (Dr Walsh).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study)
Mizuno et al.
Circulation 2008;117:494-502.
ABSTRACT | FULL TEXT  

Prevention of atherosclerosis progression in asymptomatic healthy elderly
Lees
Am. J. Clin. Nutr. 2007;86:1569S-1571S.
ABSTRACT | FULL TEXT  

Drug Treatment of Hyperlipidemia in Women
Walsh and Pignone
JAMA 2004;291:2243-2252.
ABSTRACT | FULL TEXT  

Cardiovascular Disease and Dyslipidemia in Women
Welty
Arch Intern Med 2001;161:514-522.
ABSTRACT | FULL TEXT  

Is Cholesterol a Risk Factor for Stroke?: No
Landau
Arch Neurol 1999;56:1521-1524.
FULL TEXT  

Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT | FULL TEXT  

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial
Lewis et al.
J Am Coll Cardiol 1998;32:140-146.
ABSTRACT | FULL TEXT  

Diabetes Mellitus and Cardiovascular Disease in Women
Sowers
Arch Intern Med 1998;158:617-621.
ABSTRACT | FULL TEXT  

Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association
Mosca et al.
Circulation 1997;96:2468-2482.
FULL TEXT  

A Comparison of Estrogen Replacement, Pravastatin, and Combined Treatment for the Management of Hypercholesterolemia in Postmenopausal Women
Davidson et al.
Arch Intern Med 1997;157:1186-1192.
ABSTRACT  

Treatment of Hypercholesterolemia in Women: Equality, Effectiveness, and Extrapolation of Evidence
Pearson and Myerson
JAMA 1997;277:1320-1321.
ABSTRACT  

Prevention of Coronary Heart Disease with Pravastatin
Rogers et al.
NEJM 1996;334:1333-1335.
FULL TEXT